Literature DB >> 31270390

HMGB1: meeting the need for new tools in the box.

Anne-Marie C Overstreet1, Jeannette S Messer2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31270390      PMCID： PMC7168996          DOI： 10.1038/s41385-019-0185-x

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN： 1933-0219            Impact factor:   7.313


× No keyword cloud information.
  12 in total

1.  Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation.

Authors:  Xiaorong Zhu; Jeannette S Messer; Yunwei Wang; Fanfei Lin; Candace M Cham; Jonathan Chang; Timothy R Billiar; Michael T Lotze; David L Boone; Eugene B Chang
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

Review 2.  The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis.

Authors:  Huan Yang; Daniel J Antoine; Ulf Andersson; Kevin J Tracey
Journal:  J Leukoc Biol       Date:  2013-02-27       Impact factor: 4.962

3.  Native versus recombinant high-mobility group B1 proteins: functional activity in vitro.

Authors:  Klaus Zimmermann; Dirk Völkel; Sabrina Pable; Thomas Lindner; Franziska Kramberger; Soheyl Bahrami; Friedrich Scheiflinger
Journal:  Inflammation       Date:  2004-08       Impact factor: 4.092

4.  5-Fluorouracil causes leukocytes attraction in the peritoneal cavity by activating autophagy and HMGB1 release in colon carcinoma cells.

Authors:  Lucia Cottone; Annalisa Capobianco; Chiara Gualteroni; Cristiana Perrotta; Marco E Bianchi; Patrizia Rovere-Querini; Angelo A Manfredi
Journal:  Int J Cancer       Date:  2014-08-18       Impact factor: 7.396

5.  Regulation of HMGB1 release protects chemoradiotherapy-associated mucositis.

Authors:  Keon-Il Im; Young-Sun Nam; Nayoun Kim; Yunejin Song; Eun-Sol Lee; Jung-Yeon Lim; Young-Woo Jeon; Seok-Goo Cho
Journal:  Mucosal Immunol       Date:  2019-01-15       Impact factor: 7.313

6.  High mobility group protein B1 is an activator of apoptotic response to antimetabolite drugs.

Authors:  Natalia Krynetskaia; Hongbo Xie; Slobodan Vucetic; Zoran Obradovic; Evgeny Krynetskiy
Journal:  Mol Pharmacol       Date:  2007-10-19       Impact factor: 4.436

Review 7.  High Mobility Group Box Protein 1 (HMGB1): The Prototypical Endogenous Danger Molecule.

Authors:  Huan Yang; Haichao Wang; Sangeeta S Chavan; Ulf Andersson
Journal:  Mol Med       Date:  2015-10-27       Impact factor: 6.354

Review 8.  MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.

Authors:  Rajesh V Lalla; Joanne Bowen; Andrei Barasch; Linda Elting; Joel Epstein; Dorothy M Keefe; Deborah B McGuire; Cesar Migliorati; Ourania Nicolatou-Galitis; Douglas E Peterson; Judith E Raber-Durlacher; Stephen T Sonis; Sharon Elad
Journal:  Cancer       Date:  2014-02-25       Impact factor: 6.860

Review 9.  High-Mobility Group Box-1 and Liver Disease.

Authors:  Harriet Gaskell; Xiaodong Ge; Natalia Nieto
Journal:  Hepatol Commun       Date:  2018-09-07

10.  Anthocyanins Extracted from Oryza sativa L. Prevent Fluorouracil-Induced Nuclear Factor-κB Activation in Oral Mucositis: In Vitro and In Vivo Studies.

Authors:  Salunya Tancharoen; Prana Shakya; Somphong Narkpinit; Pornpen Dararat; Kiyoshi Kikuchi
Journal:  Int J Mol Sci       Date:  2018-09-29       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.